Adaptive Biotechnologies Corporation
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $70.5M | $47.9M | $65.1M | $90.0M | $139.1M | $123.4M | $96.6M | $55.0M |
| Accounts Receivable | $50.4M | $41.7M | $38.0M | $40.1M | $17.4M | $10.0M | $12.7M | $4.8M |
| Inventory | $9.8M | $8.4M | $14.4M | $14.5M | $19.3M | $14.1M | $9.1M | $7.8M |
| Total Current Assets | $300.2M | $283.8M | $410.2M | $562.1M | $402.7M | $726.9M | $612.7M | $180.7M |
| Property, Plant & Equipment | $34.1M | $48.6M | $68.2M | $83.4M | $85.3M | $39.7M | $60.4M | $19.1M |
| Goodwill | $119.0M | $119.0M | $119.0M | $119.0M | $119.0M | $119.0M | $119.0M | $119.0M |
| Intangible Assets (Excl. Goodwill) | $1.7M | $3.4M | $5.1M | $6.8M | $8.5M | $10.2M | $11.9M | $13.6M |
| Total Assets | $512.7M | $539.4M | $661.1M | $856.6M | $923.3M | $1.12B | $912.3M | $332.7M |
| Liabilities | ||||||||
| Accounts Payable | $6.5M | $7.3M | $7.7M | $8.1M | $3.3M | $3.2M | $4.5M | $1.8M |
| Total Current Liabilities | $89.9M | $98.1M | $88.0M | $109.8M | $113.8M | $105.2M | $78.3M | $22.8M |
| Long-Term Debt | $126.6M | $132.4M | $130.7M | $125.4M | — | — | — | — |
| Total Liabilities | $287.7M | $336.9M | $352.9M | $392.5M | $319.2M | $373.1M | $341.3M | $29.9M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-1.36B | $-1.30B | $-1.14B | $-919.1M | $-718.9M | $-511.6M | $-365.5M | $-295.9M |
| Total Stockholders' Equity | $218.8M | $202.7M | $308.4M | $464.2M | $604.0M | $743.3M | $571.0M | $-258.1M |